Ipsen and Syntaxin collaborate on botulinum research
This article was originally published in Scrip
Executive Summary
Ipsen and Syntaxin are to collaborate on a second drug discovery programme in the field of botulinum toxins, though the companies are not revealing details of either of their research programmes. Ipsen participated in Syntaxin's £18 million series C financing last November, which is when the first deal was signed.